Clinical and Experimental Dermatology最新文献

{"title":"Multiple subcutaneous reactive angioendotheliomatosis in a patient with antiphospholipid syndrome.","authors":"Takashi Yokoyama, Masato Nakaguro, Mariko Ogawa-Momohara, Yoshihisa Nakano, Ryo Fukaura, Takuya Takeichi, Yoshinao Muro, Masashi Akiyama","doi":"10.1093/ced/llae223","DOIUrl":"10.1093/ced/llae223","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1452-1455"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141260865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial.","authors":"Stephen Tyring, Angela Moore, Akimchi Morita, H Chih-Ho Hong, In-Ho Song, Jason Eccleston, Gweneth Levy, Mohamed-Eslam F Mohamed, Yuli Qian, Tianshuang Wu, Anqi Pan, Kinjal Hew, Kim A Papp","doi":"10.1093/ced/llae152","DOIUrl":"10.1093/ced/llae152","url":null,"abstract":"<p><strong>Background: </strong>Dysregulated interleukin (IL)-17/IL-23 signalling contributes to psoriasis pathogenesis. Cedirogant is an inverse agonist of nuclear receptor ROR-gamma isoform 2 (RORyt), a key transcription factor responsible for IL-17 synthesis and a regulator of the T helper 17 cell lineage programme.</p><p><strong>Objectives: </strong>To evaluate the efficacy and safety of cedirogant to treat moderate-to-severe psoriasis.</p><p><strong>Methods: </strong>In this phase IIb, multicentre, double-blind, 16-week study (NCT05044234), adults aged 18-65 years were randomized 1 : 1 : 1 : 1 to once-daily oral cedirogant 75 mg, 150 mg, 375 mg or placebo. Assessments included: ≥ 50%/75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index (PASI 50/75/90/100), static Physician's Global Assessment 0/1, Psoriasis Symptoms Scale 0 and improvements in itch; adverse events (AEs); pharmacokinetics; and IL-17A/F biomarker levels. Efficacy results based on observed cases were summarized descriptively.</p><p><strong>Results: </strong>Of 156 enrolled patients, most were male (70.5%); 39 patients were randomized to each treatment. Only 47 patients completed the study; the study was terminated early owing to preclinical findings. At week 16, PASI 75 achievement rates (primary endpoint) were 29%, 8% and 42% in the cedirogant 75-mg, 150-mg and 375-mg groups, respectively, and 0% in the placebo group. AE rates were similar in the cedirogant 75-mg, 150-mg and placebo groups, and higher in the cedirogant 375-mg group; most AEs were mild or moderate.</p><p><strong>Conclusions: </strong>Patients with psoriasis who received cedirogant showed PASI improvement, and cedirogant was generally well tolerated. The results should be interpreted in the context of early study termination. Cedirogant development has been discontinued.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1347-1355"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and laboratory findings characterizing the need for systemic corticosteroids and nonsteroidal systemic therapies and the predicted outcomes in cutaneous polyarteritis nodosa: a single-centre retrospective analysis.","authors":"Ryo Tanaka, Keiji Tanese, Yoshihiro Ito, Sakiko Takeuchi, Ari Morimoto, Kazuyo Sujino, Masayuki Amagai, Akiko Tanikawa","doi":"10.1093/ced/llae143","DOIUrl":"10.1093/ced/llae143","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous polyarteritis nodosa (cPN) is a necrotizing arteritis of medium-sized vessels limited to the skin. Because of its rarity and the diversity of its clinical manifestations, there is no consensus treatment. Moreover, there are no established indicators that predict disease severity or its outcome.</p><p><strong>Objectives: </strong>To investigate clinicolaboratory features that predict patients requiring systemic therapy, including corticosteroids, to control disease activity.</p><p><strong>Methods: </strong>Thirty-six patients with cPN who had not received systemic corticosteroids at their initial visit were retrospectively analysed by correlating the treatment and its response with clinicolaboratory findings.</p><p><strong>Results: </strong>The major medications administered were antiplatelet agents [64% (23/36)], vasodilators [39% (14/36)] and prednisolone (PSL) [36% (13/36)]. In total, 23 patients achieved remission without PSL, 5 were managed with compression therapy alone or even observation and 18 received antiplatelet monotherapy or combined with vasodilator/dapsone whereas 13 required PSL. Of the 13 who required PSL, 10 achieved remission with PSL monotherapy or PSL and single/multiple medications and 3 with PSL and multiple drugs then failed to achieve remission and underwent limb amputation. There were more skin ulcers and an elevated peripheral white blood cell (WBC) count and erythrocyte sedimentation rate (ESR) before corticosteroid induction in patients requiring PSL. Three patients with treatment failure had a markedly elevated ESR (> 50 mm h-1).</p><p><strong>Conclusions: </strong>More than half of patients with cPN can achieve remission without corticosteroids. An elevated WBC, an elevated ESR and the presence of skin ulcers predict the need for PSL. A high ESR before corticosteroid induction predicts treatment resistance, even with PSL.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1338-1346"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune reconstitution is the trigger of herpes zoster with lymphopenia and high neutrophil-to-lymphocyte ratio in a retrospective cohort study.","authors":"Takenobu Yamamoto, Yumi Aoyama","doi":"10.1093/ced/llae176","DOIUrl":"10.1093/ced/llae176","url":null,"abstract":"<p><strong>Background: </strong>Herpes zoster (HZ) rarely results in subsequent death, but predictive biomarkers for mortality necessitate further elucidation.</p><p><strong>Objectives: </strong>To investigate immune dynamics prior to an HZ event, risk factors for HZ onset and immune status at initial HZ.</p><p><strong>Methods: </strong>This retrospective study extracted from patient records the absolute neutrophil and lymphocyte counts (ANC and ALC, respectively) at the initial HZ date of appearance and up to 30 days before HZ. A follow-up survey was completed within 180 days of onset of illness.</p><p><strong>Results: </strong>Patients with HZ showed a higher neutrophil-to-lymphocyte ratio (NLR) and lower ALC than patients in the control group at the initial date and had a poorer prognosis. In the pre-onset examination, the maximum and minimum ALC values were significantly lower in patients with HZ than in the control group, and the maximum ALC value in patients with HZ was lower than the minimum value in the control group. The lowest ALC was observed 7 days before the onset of HZ. An NLR of 4.53 or more and an ALC of 0.64 × 109 cells L-1 or less were predictive markers of HZ development within 30 days. Patients who died after HZ had a lower minimum ALC than those who survived longer.</p><p><strong>Conclusions: </strong>HZ develops in a state of immune reconstitution in patients with immunocompromised conditions, as part of 'unmasking' the immune reconstitution inflammatory syndrome. Lymphopenia prior to HZ onset is one of the most crucial factors in its pathogenesis and vital prognosis. Limitations of the study were small population size, varying age distribution, retrospective nature, and potential overestimation of pre-onset data.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1372-1378"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National epidemiology of digital papillary adenocarcinoma in England 2013-2020: a population-based registry study.","authors":"Kashini Andrew, Birgitta van Bodegraven, Sally Vernon, Mariam Balogun, Paul Craig, Neil Rajan, Zoe C Venables, Simon Tso","doi":"10.1093/ced/llae203","DOIUrl":"10.1093/ced/llae203","url":null,"abstract":"<p><strong>Background: </strong>Digital papillary adenocarcinoma (DPA), formerly known as aggressive DPA, is a rare adnexal cancer of sweat gland differentiation with metastatic potential. DPA epidemiology and patient outcome data are prerequisites for developing diagnostic and therapeutic guidance, which are lacking for this rare cancer.</p><p><strong>Objectives: </strong>To report the incidence, patient demographics and treatment of patients with DPA in England from 1 January 2013 to 31 December 2020 using national cancer registry data.</p><p><strong>Methods: </strong>DPA diagnoses in England during 2013-2020 were identified from the National Cancer Registration and Analysis Service dataset using morphology and behaviour codes. These were registered from routinely collected pathology reports, along with cancer outcomes and services datasets. The 2013 European age-standardized incidence rates (EASRs) were calculated.</p><p><strong>Results: </strong>In total, 36 cases of DPA (7 in women and 29 in men) were diagnosed. The median age at diagnosis for the cohort was 54 years (interquartile range 46-64). The most frequently affected sites were the upper limbs (81%). All patients in the cohort received surgical excisions. The EASR was 0.10 (95% confidence interval 0.07-0.14) per 1 000 000 person-years.</p><p><strong>Conclusions: </strong>This study reports the incidence and variation of DPA in England between 2013 and 2020. DPA was more common in older men and predominantly affected the upper limbs. This finding supports the need to develop a national policy for the reporting and management of DPA as well as development of a clinical guideline.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1389-1395"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140954869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omega-3 fatty acids mitigate isotretinoin-induced cheilitis.","authors":"Chawalpat Siripanich, Yan Ching Chow, Faisal R Ali","doi":"10.1093/ced/llae197","DOIUrl":"10.1093/ced/llae197","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1444-1445"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence algorithms and three-dimensional volumetric rendering for basal cell carcinoma detection and tumour depth assessment in reflectance confocal microscopy-optical coherence tomography images: a pilot study.","authors":"Alexander Pan, Nathalie de Carvalho, Luisa Silva, Ucalene Harris, Stephen Dusza, Aditi Sahu, Kivanc Kose, Jilliana Monnier, Chih-Shan Chen, Manu Jain","doi":"10.1093/ced/llae213","DOIUrl":"10.1093/ced/llae213","url":null,"abstract":"<p><p>The reflectance confocal microscopy (RCM)-optical coherence tomography (OCT) device has shown utility in detecting and assessing the depth of basal cell carcinoma (BCC) in vivo but is challenging for novices to interpret. Artificial intelligence (AI) applied to RCM-OCT could aid readers. We trained AI models, using OCT rasters of biopsy-confirmed BCC, to detect BCC, create three-dimensional rendering and automatically measure tumour depth. Trained AI models were applied to a separate test set containing rasters of BCC, benign lesions, and healthy skin. Blinded reader analysis and tumour depth correlation with histopathology were conducted. BCC detection improved from viewing OCT rasters only (sensitivity 73.3%, specificity 45.5%) to viewing rasters with AI-generated BCC rendering (sensitivity 86.7%, specificity 48.5%). A Pearson correlation r2 = 0.59 (P = 0.02) was achieved for the tumour depth measurement between AI and histological measured depths. Thus, addition of AI to the RCM-OCT device may expand its utility widely.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1420-1423"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey of Scottish Dermatological Society members on the new Medicines and Healthcare products Regulatory Agency isotretinoin recommendations.","authors":"Faisal Dubash, Robert Dawe, Andrew Affleck","doi":"10.1093/ced/llae230","DOIUrl":"10.1093/ced/llae230","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1437-1439"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of adult-onset Still disease with eyelid xanthogranuloma mimicking Erdheim-Chester disease.","authors":"Keigo Hirafuku, Masahiro Kanbe, Itaru Dekio, Ken Yoshida, Daitaro Kurosaka, Akira Honda, Mineo Kurokawa, Akihiko Asahina","doi":"10.1093/ced/llae232","DOIUrl":"10.1093/ced/llae232","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1439-1441"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the burden of actinic keratoses through development of a patient decision aid: a mixed-methods study.","authors":"Ciara Drumm, Aoife Moloney, Louise Fleming, Imelda Morgan, Ciara Keating, Clodagh Hughes, Roisin Dolan, Bláithín Moriarty, Aoife Lally","doi":"10.1093/ced/llae173","DOIUrl":"10.1093/ced/llae173","url":null,"abstract":"<p><strong>Background: </strong>Actinic keratoses (AKs) are present on sun-exposed sites and are considered precursors of cutaneous squamous cell carcinoma. A better understanding of the experiences of patients with this condition may improve patient-provider relationships and guide the introduction of shared decision-making (SDM) to treatment decisions.</p><p><strong>Objectives: </strong>To develop a patient decision aid (PDA) for field treatment of multiple AKs in line with the International Patient Decision Aid Standards (IPDAS) by (i) characterizing the burden and lived experiences of patients with multiple AKs, (ii) understanding the decisional needs of patients requiring field treatment, and (iii) exploring clinician preferences regarding field treatment for multiple AKs.</p><p><strong>Methods: </strong>This mixed-methods study followed the most up-to-date guidelines set out by the IPDAS collaboration; a voluntary body that aims to enhance the quality of PDAs by developing an evidence-based systematic process for the development of unbiased and effective PDAs.</p><p><strong>Results: </strong>Multiple AKs have a psychosocial impact on patients. Patients feel supported through the integration of evidence-based information to guide SDM.</p><p><strong>Conclusions: </strong>We propose that the use of a PDA for multiple AKs provides a key role in supporting informed shared patient-provider decision-making and empowers patient involvement in their prospective treatment strategy.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1379-1388"},"PeriodicalIF":3.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}